New drug cocktail aims to beat leukemia in patients too frail for standard chemo
NCT ID NCT07172204
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is testing a combination of two drug regimens—VA (venetoclax and azacitidine) and low-dose CHA (cladribine, homoharringtonine, and cytarabine)—given in alternating cycles to newly diagnosed acute myeloid leukemia (AML) patients aged 60 or older who cannot tolerate intensive chemotherapy. The goal is to see if this approach can clear leukemia cells from the bone marrow (MRD negativity) and improve outcomes. The study will enroll 25 participants across multiple centers in China.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Venetoclax, azacitidine, cladribine, homoharringtonine, and cytarabine
What this could lead to
If successful, this could offer a more effective treatment option for older or frail AML patients who cannot tolerate standard chemotherapy, potentially leading to better disease control and longer remission.
What could go wrong
This is a small, early-phase (phase II) study with only 25 participants, so results may not apply to all patients. The drug combination also carries risks like infection, bleeding, and organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE 60 AND OLDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Chao-Yang Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shenzhen University General Hospital
RECRUITINGShenzhen, Guangdong, China
Contact Phone: •••-•••-••••
-
the First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
the Second Affiliated Hospital of Nanchang University
RECRUITINGNanchang, Jiangxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••